[207] T. Ngandu et al., “A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.,” Lancet (London, England), vol. 385, no. 9984, pp. 2255–2263, Jun. 2015, doi: 10.1016/S0140-6736(15)60461-5.
[208] M. Kivipelto, F. Mangialasche, and T. Ngandu, “Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease.,” Nat. Rev. Neurol., vol. 14, no. 11, pp. 653–666, Nov. 2018, doi: 10.1038/s41582-018-0070-3.
[209] R. Nelson, “HRT Update Regarding Breast Cancer Risk Advised in EU,” Medscape Medical News.
[210] Collaborative Group on Hormonal Factors in Breast Cancer, “Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence,” Lancet (London, England), vol. 394, no. 10204, pp. 1159–1168, Sep. 2019, doi: 10.1016/S0140-6736(19)31709-X.
[211] E. Cordina-Duverger et al., “Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.,” PLoS One, vol. 8, no. 11, p. e78016, 2013, doi: 10.1371/journal.pone.0078016.
[212] R. T. Chlebowski and J. E. Manson, “Menopausal Hormone Therapy and Breast Cancer,” Cancer J., vol. 28, no. 3, pp. 169–175, May 2022, doi: 10.1097/PPO.0000000000000601.
[213] R. T. Chlebowski and A. K. Aragaki, “The Women’s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context,” Menopause, vol. 30, no. 4, pp. 454–461, Apr. 2023, doi: 10.1097/GME.0000000000002154.
[214] J. Yuk, “Relationship between menopausal hormone therapy and breast cancer: A nationwide population‐based cohort study,” Int. J. Gynecol. Obstet., Mar. 2024, doi: 10.1002/ijgo.15461.
[215] C. Schneider, S. S. Jick, and C. R. Meier, “Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations,” Climacteric, vol. 12, no. 6, pp. 514–524, Dec. 2009, doi: 10.3109/13697130903075352.
[216] Z. Yang, Y. Hu, J. Zhang, L. Xu, R. Zeng, and D. Kang, “Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis.,” Gynecol. Endocrinol., vol. 33, no. 2, pp. 87–92, Feb. 2017, doi: 10.1080/09513590.2016.1248932.
[217] H. Hamoda et al., “BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020,” Post Reprod. Heal., vol. 27, no. 1, pp. 49–55, Mar. 2021, doi: 10.1177/2053369120983154.
[218] R. T. Chlebowski et al., “Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials,” JAMA, vol. 324, no. 4, p. 369, Jul. 2020, doi: 10.1001/jama.2020.9482.
[219] J. G. Greene, “Constructing a standard climacteric scale.,” Maturitas, vol. 29, no. 1, pp. 25–31, May 1998, doi: 10.1016/s0378-5122(98)00025-5.
[220] “Порог вмешательства на основании определения 10-летнего абсолютного риска основных остеопоротических переломов”, [Online]. Available: https://osteoporosis-russia.ru/frax/